Back to top
Top
DERep Home Page

["Allergy, Intolerance": "Substance with beta adrenergic receptor antagonist mechanism of action (substance)"]

Performance/Reporting Period
2021
Direct Reference Code

Constrained to 'Substance with beta adrenergic receptor antagonist mechanism of action (substance)' SNOMEDCT code

QDM Datatype and Definition (QDM Version 5.5 Guidance Update)

"Allergy Intolerance"

Data elements that meet criteria using this datatype should document the allergy or intolerance and its corresponding value set.

Timing:

  • The prevalence period references the time from the onset date to the abatement date. Often an abatement date is not present as allergy or intolerance is ongoing.
  • The author dateTime references the recorded time.
eCQMs using this data element:
CMS144v9 - Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS145v9 - Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF less than 40%)
QDM Attributes

prevalencePeriod

Prevalance Period is the time from onset dateTime to abatement dateTime.
Last Updated: Jul 08, 2021